Incyte Corp. closed 18.70% short of its 52-week high of $83.95, which the company achieved on November 8th.

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

Sun Pharmaceutical Industries said that it has launched hair-loss treatment drug LEQSELVI (deuruxolitinib) in the U.S.

Indian drugmaker Sun Pharmaceutical Industries together with its subsidiaries announced that further to its intimation dated ...

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Incyte ...

Incyte Corp. closed 16.64% below its 52-week high of $83.95, which the company achieved on November 8th.

Sun Pharma settles litigation with Incyte, gains license for alopecia treatment, launches LEQSELVI tablet in the US.

Sun Pharma settles litigation with Incyte over Leqselvi, launches product for severe alopecia areata treatment in the US.

After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...

In a joint statement, the companies announced that both parties will withdraw the ongoing lawsuit and release each other from ...